Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition...

Area of Science:

• Molecular Biology
• Medicinal Chemistry
• Oncology

Background:

• Signal transducer and activator of transcription 3 (STAT3) is a key transcription factor regulating cell proliferation, metastasis, angiogenesis, immune response, and chemoresistance.
• While STAT3 is transiently active in normal cells, its persistent activation is common in cancers, correlating with poor prognosis and tumor progression.
• Targeting STAT3 presents a promising therapeutic strategy for various cancers.

Purpose of the Study:

• To systematically review the progress in the discovery of small-molecule inhibitors and degraders targeting STAT3 over the past five years.
• To focus on the structural features, design strategies, and bioactivities of these STAT3-targeting agents.
• To provide insights for future drug design and optimization of STAT3 inhibitors and degraders.

Main Methods:

• Systematic literature review of studies published in the last 5 years.
• Analysis of structural characteristics, design methodologies, and biological activities of STAT3 inhibitors and degraders.
• Focus on small-molecule compounds.

Main Results:

• Several small-molecule STAT3 inhibitors and degraders have been discovered and advanced into clinical trials.
• Detailed analysis of the structural features and design strategies employed in developing these agents.
• Summary of their demonstrated bioactivities in preclinical and clinical settings.

Conclusions:

• STAT3 remains a critical target for cancer therapy, with ongoing development of novel inhibitors and degraders.
• Understanding structural features and design strategies is crucial for optimizing STAT3-targeting drug discovery.
• Continued research in this area holds promise for accelerating the development of effective STAT3-based cancer treatments.